Sectors

IMTX
Immatics N.V.
9.30
1 x 9.24
1 x 9.38
bid
ask
-
0.11
1.12%
10:36 AM
timesize
Ytd-11.38%
1y56.65%
9.27
day range
9.50
5.05
52 week range
12.41
Open9.27Prev Close9.41Low9.27High9.50Mkt Cap1.26B
Vol9.74KAvg Vol473.33KEPS-1.99P/E-4.73Forward P/E-5.09
Beta1.32Short Ratio10.25Inst. Own79.47%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg10.13200-d Avg10.131yr Est18.89

IMTX News

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
globenewswire.com
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or t

Immatics: PRAME Is Becoming More Than A Single-Asset Story
seekingalpha.com
Immatics: PRAME Is Becoming More Than A Single-Asset Story

Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
globenewswire.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASC

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
globenewswire.com
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous P

IMA401 achieved deep and durable responses in various indications, including melanoma and head and n

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
globenewswire.com
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Can

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expans

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
zacks.com
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate

Immatics Announces First Quarter 2026 Financial Results and Business Update
globenewswire.com
Immatics Announces First Quarter 2026 Financial Results and Business Update

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggere

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
zacks.com
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
globenewswire.com
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific

Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or

PRAME-directed Cell Therapy Using Immatics’ TCR  Induces Deep and Durable Remission in Pediatric Patient  with Advanced Metastatic Nephroblastoma
globenewswire.com
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Pat

Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Hei

SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX
defenseworld.net
SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fou

Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts
defenseworld.net
Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
seekingalpha.com
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a rob

Immatics (NASDAQ:IMTX) Trading Down 5%  – Here’s What Happened
defenseworld.net
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock tra

Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts
defenseworld.net
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been given an average recommendation o

Immatics (NASDAQ:IMTX) Stock Price Up 3.9%  – Should You Buy?
defenseworld.net
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

Immatics N.V. (NASDAQ: IMTX - Get Free Report) shot up 3.9% on Wednesday. The stock traded as high a

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 807 companies reached new 52-week lows.